Valuation: Lipocine Inc.

Market Cap 17.81M 15.56M 14.63M 13.35M 25.05M 1.7B 25.06M 176M 67.74M 869M 66.87M 65.41M 2.8B P/E 2026 *
-1.4x
P/E 2027 * -1.61x
Enterprise Value 17.81M 15.56M 14.63M 13.35M 25.05M 1.7B 25.06M 176M 67.74M 869M 66.87M 65.41M 2.8B EV / Sales 2026 *
28.2x
EV / Sales 2027 * 23.9x
Free-Float
95.49%
Yield 2026 *
-
Yield 2027 * -
1 day+0.69%
1 week-1.14%
Current month-3.57%
1 month+3.35%
3 months-5.68%
6 months-69.79%
Current year-73.10%
1 week 2.1
Extreme 2.1
2.25
1 month 2.05
Extreme 2.0501
2.5
Current year 1.81
Extreme 1.81
12.37
1 year 1.81
Extreme 1.81
12.37
3 years 1.81
Extreme 1.81
12.37
5 years 1.81
Extreme 1.81
32.13
10 years 1.81
Extreme 1.81
100.3
Manager TitleAgeSince
Chief Executive Officer 69 31/12/1996
Chief Tech/Sci/R&D Officer 56 30/11/2022
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 69 07/01/2014
Director/Board Member 58 31/12/2002
Chairman 73 19/04/2026
Date Insider Type Main position Quantity % Market Cap. Importance
03/08/26 Free

Director

2,000 0.0243%
03/06/26 Free

Director

1,764 0.0214%
03/06/26 Free

Chairman

1,764 0.0214%
Change 5-day change 1-year change 3-year change Capi.($)
-3.57%-1.14%-24.48%-35.33% 17.81M
-0.07%+7.14%+53.95%+111.00% 74.27B
-0.79%-0.09%+35.22%+77.66% 61.21B
+0.28%+5.73%+33.67%+20.82% 27.55B
-0.15%+0.75%-16.69%+361.67% 26.38B
+2.93%+4.32%+2.18%-3.60% 25.34B
+0.88%+3.89%+25.86%-8.89% 20.84B
-1.47%+4.86%-5.94%+519.63% 14.94B
+0.87%-3.73%+159.95%+327.53% 15.17B
+1.63%+2.20%+46.92%+170.72% 14.41B
Average +0.47%+2.74%+31.06%+154.12% 28.01B
Weighted average by Cap. +0.18%+3.44%+36.62%+135.75%

Financials

2026 *2027 *
Net sales 631K 552K 518K 473K 888K 60.35M 888K 6.22M 2.4M 30.82M 2.37M 2.32M 99.35M 745K 651K 612K 558K 1.05M 71.22M 1.05M 7.34M 2.83M 36.37M 2.8M 2.74M 117M
Net income -12.64M -11.05M -10.38M -9.48M -17.78M -1.21B -17.79M -125M -48.09M -617M -47.48M -46.44M -1.99B -16.22M -14.17M -13.32M -12.16M -22.81M -1.55B -22.82M -160M -61.69M -792M -60.9M -59.57M -2.55B
Net Debt - -
Logo Lipocine Inc.
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Employees
14
Date Price Change Volume
22/09/26 US$2.160 -3.57% 64,403
21/09/26 US$2.240 +1.36% 16,716
18/09/26 US$2.210 -0.45% 48,485
17/09/26 US$2.220 +2.78% 43,866
16/09/26 US$2.160 -1.14% 64,031
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.160USD
Average target price
5.000USD
Spread / Average Target
+131.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LPCN Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!